Enforcement Report - Week of April 24, 2024
Enforcement Report - Week of March 27, 2024
Enforcement Report - Week of September 13, 2023
Marlex Pharma Issues Voluntary Nationwide Recall of Digoxin Tablets USP,
Amici's Generic Digoxin Receives Approval in the U.S.
Aurobindo Pharma's Generic Digoxin Receives Approval in the U.S.
Novitium Pharma's Generic Digoxin Receives Approval in the US
The heart disease drug digoxin tamped down the inflammatory molecule IL-17A in mouse models of obesity, promoting weight loss, researchers reported.
Chlorhexidine Gluconate (CHG) Solution Market (By Major Eminent Players, Types, Applications, and Leading Regions) Segments Outlook, Business Assessment, Competition Scenario, Trends and Forecast by Upcoming Years. The study of the Chlorhexidine Gluconate (CHG) Solution market report is done based on the noteworthy research methodology that provides the analytical inspection of the global market based on various segments the Industry is alienated into also the summary and Advance size of the marketplace owing to the various outlook possibilities. The report also gives information about the key players of the Chlorhexidine Gluconate (CHG) Solution Industry by different features that include the Chlorhexidine Gluconate (CHG) Solution overview of the companies, the portfolio of the product and also the revenue facts from Period of Forecast, As Well. It presents a 360-degree overview of the competitive landscape of the industries. SWOT Analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Chlorhexidine Gluconate (CHG) Solution market is showing steady growth and CAGR is expected to improve during the forecast period.
C2 Pharma s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), digoxin. In early March, the API was listed for its potential to reduce the symptoms of COVID-19 patients in combination with other anti-viral drugs based on initial research in South Korea and India.